Annals of Intensive Care volume 1, Article number: 6 (2011)
Depression of left ventricular (LV) intrinsic contractility is constant in patients with septic shock. Because most parameters of cardiac function are strongly dependent on afterload, especially in this context, the cardiac performance evaluated at the bedside reflects intrinsic contractility, but also the degree of vasoplegia. Recent advances in echocardiography have allowed better characterization of septic cardiomyopathy. It is always reversible providing the patient's recovery. Unlike classic cardiomyopathy, it is not associated with high filling pressures, for two reasons: improvement in LV compliance and associated right ventricular dysfunction. Although, it is unclear to which extent it affects prognosis, a hyperkinetic state is indicative of a profound and persistent vasoplegia associated with a high mortality rate. Preliminary data suggest that the hemodynamic response to a dobutamine challenge has a prognostic value, but large studies are required to establish whether inotropic drugs should be used to treat this septic cardiac dysfunction.
Reversible myocardial depression in patients with septic shock was first described in 1984 by Parker et al. using radionuclide cineangiography . In a series of 20 patients, they reported a 65% incidence of left ventricular (LV) systolic dysfunction, defined by an ejection fraction <45% . In 1990, using transthoracic echocardiography, Jardin et al. reported the same results . In a canine model simulating human septic shock, Natanson et al. demonstrated that intrinsic LV performance was actually depressed in all animals and not corrected by volume expansion . Finally, more recently, Barraud et al. confirmed the presence of severe depressed intrinsic LV contractility using LV pressure/volume loops in lipopolysaccharide-treated rabbits . All of these studies, and many others not cited in this introduction, demonstrate the reality of the impairment of intrinsic LV contractility in septic shock. For many years, septic cardiac dysfunction was largely underestimated because the hemodynamic device used, i.e., the pulmonary artery catheter, was not appropriate for establishing such a diagnosis. Development of new hemodynamic tools at the bedside, such as echocardiography, allowed better characterization of the septic cardiomyopathy . The following review explains the mechanisms of such a depression, its characteristics, incidence, and finally its impact on treatment and prognosis. We decided not to deal with the place and the role of biomarkers, which will be presented in a future review of the journal.
Many factors may contribute to cardiac depression during sepsis. Studies performed in humans have ruled out coronary hypoperfusion requiring coronary intervention as a cause of LV systolic dysfunction in sepsis [6, 7]. Of course, patients with coronary disease may behave differently.
On the other hand, the role of cytokines has been strongly advocated in the genesis of septic cardiomyopathy. In 1985, Parrillo et al. demonstrated in vitro that myocardial cell shortening is reduced by exposure to the serum of septic patients . Later, the same team showed that the circulating factor responsible for this was tumor necrosis factor α (TNF-α) [9, 10], even though later studies have implicated other cytokines, such as interleukin-1β . Kumar et al. suggested that the effect of cytokines on cardiac myocytes results from an increase in intracellular cGMP and in nitric oxide . In addition, direct alteration in cellular respiration with mitochondrial dysfunction also was advocated , and, finally, Tavernier et al. suggested that increased phosphorylation of troponin I was involved by reducing myofilament response to Ca2+ .
Main characteristics of septic cardiomyopathy
The first characteristic of septic cardiomyopathy is that it is acute and reversible, providing the patient recovers. In 90 patients during a 5-year period, Jardin et al. reported that LV ejection fraction is normalized in a few days , as also reported more recently by Bouhemad et al. .
The second characteristic, which is crucial to full understanding, is that depressed LV systolic function is associated with normal or low LV filling pressure, unlike the "classic" pattern of cardiogenic shock where LV pressures are elevated (Figure 1). This may explain why the pulmonary artery catheter has for many years underestimated the incidence of LV systolic dysfunction. Jardin et al. and Bouhemad et al. reported an average pulmonary capillary wedge pressure close to 11 mmHg in patients with decreased LV ejection fraction, which is not significantly different from that found in patients with a preserved ejection fraction [2, 16]. In the study by Parker et al., the pulmonary capillary wedge pressure was 14 mmHg on average in patients with LV ejection fraction <45% .
Two mechanisms may explain this absence of elevated LV pressures. The first relates to the frequent association with right ventricular (RV) dysfunction. Vincent et al. in a group of 93 patients with septic shock reported a decreased RV ejection fraction compared with a "control" group . Similar results were found by Kimchi et al. and Parker et al. [18, 19]. Using transesophageal echocardiography, we reported that almost 30% of patients have RV dilatation, which is highly suggestive of significant RV dysfunction (Figure 2) . RV dysfunction is related to acute pulmonary hypertension, which is frequently associated in this situation because of the acute lung injury, or depressed intrinsic contractility due to circulating cytokines . It protects the pulmonary circulation  and avoids significant elevation of LV pressures.
The second mechanism relates to LV compliance alteration, which usually occurs. In their original work, Parker et al. suggested a huge increase in LV compliance; they found a dilatation of the left ventricle of more than 100% . This very impressive LV "preload adaptation" was actually never confirmed and was probably explained in part by technical errors related to the use of the pulmonary artery catheter. Most studies using echocardiography only report a slight increase in LV size in patients with decreased LV ejection fraction compared with patients with preserved ejection fraction, suggesting a true but slight increase in LV compliance in these patients (Table 1) [16, 20, 22]. In 12 normal healthy volunteers, Suffredini et al. demonstrated that injection of endotoxin induces a depression of LV systolic function associated with a significant decrease in the ratio of pulmonary capillary wedge pressure to LV end-diastolic volume index . A limited but significant increase in LV end-diastolic volume (+15%) was reported after volume loading with a pulmonary capillary wedge pressure less augmented than in the control group .
The reported incidence of LV systolic dysfunction varies significantly (Table 2). This is easy to understand, because the LV afterload plays a crucial role in the evaluation of cardiac function. As well illustrated by Robotham et al. , the same value of LV ejection fraction may correspond to very different levels of intrinsic LV contractility: for instance, an ejection fraction of 60% may correspond to a severe impairment of LV contractility, if the afterload is very low, as it is in septic shock before resuscitation. As shown by all animal studies, we must consider that the presence of depressed LV intrinsic performance is constant in septic shock. Accordingly, LV ejection fraction actually reflects the LV afterload rather than the intrinsic contractility. During the 6 first hours of resuscitation, we found an 18% incidence of a hypokinetic profile, associating low cardiac index and decreased LV ejection fraction . In another study, where echocardiography was performed later, we reported a 40% incidence of LV systolic dysfunction after 24 hours of resuscitation . In the same study, the incidence increased to 60% after 2 and 3 days , probably because of the restoration of a normal LV afterload by norepinephrine or by the natural evolution of the infectious process. This is why echocardiography, when repeated at different times, may show how norepinephrine infusion may unmask poor intrinsic LV contractility (Figure 3). Interestingly, in the study by Jardin et al., the systemic vascular resistances were significantly lower in patients with a preserved LV ejection fraction than in patients with decreased ejection fraction . A similar result was reported by Parker et al. . In our study, 15% of patients after 6 hours had a hyperkinetic profile, associating tachycardia, supra-normal LV ejection fraction, small LV cavity despite massive volume expansion, and high cardiac index--a pattern reflecting persistent and very profound vasoplegia . In 2003, we reported a series of 183 patients with septic shock who were all monitored hemodynamically by using echocardiography through transthoracic or transesophageal route . As shown in Figure 4, the relationship between LV ejection fraction and cardiac index may be separated into four parts, depending on LV afterload, volemia, and RV function.
Prognosis and treatment
It is very difficult to establish whether septic cardiomyopathy independently affects the prognosis of patients with septic shock, because many other variables are involved, such as age, patient history, type of microorganisms, and time to resuscitation. Initially, Parker et al. suggested that development of septic cardiomyopathy was "protective" . Ten of the 13 survivors had an LV ejection fraction <40%, but none of the nonsurvivors . In appearance, we found different results with a mortality rate of 43% in patients with a hypokinetic profile compared with 24% in patients with a normokinetic profile . We also found that patients with a hyperkinetic profile (small left ventricle, supranormal ejection fraction, tachycardia, high cardiac index) had a 100% mortality rate . Actually, rather than a "protective" effect of LV systolic dysfunction, we can conclude that the prognosis is poor in the presence of a hyperkinetic state, which reflects persistent and profound vasoplegia, as explained above. Table 3 summarizes the main studies and their results in terms of survival and LV systolic function.
Three therapeutic interventions must be discussed. The first is volume expansion. Parker et al. suggested that "massive" fluid infusion maintains a normal cardiac index, despite a significantly impaired LV contractility, through LV preload adaptation . However, we have learned that this dilatation is limited and that fluid overload is deleterious for survival [26, 27]. In the study by Ognibene et al., volume infusion was unable to restore normal left ventricular function and unmasked a flat Frank-Starling curve in the 21 patients with septic shock . In our study, LV stroke index and LV end-diastolic volume did not correlate, whereas LV stroke index and LV ejection fraction were strongly correlated . Nevertheless, volume expansion must always be proposed first to restore central blood volume in the case of absolute or relative hypovolemia.
The second therapeutic option is the infusion of an inotropic drug, such as dobutamine, a beta-agonist agent. We and others reserve this treatment for patients with persistent shock, lactic acidosis, and oliguria [25, 29]. In this situation, dobutamine increases LV ejection fraction and cardiac index [25, 29]. To which extent such a treatment may improve the patient's prognosis is unknown. However, it is well established that the cardiovascular response to dobutamine stress predicts outcome in sepsis. Vallet et al. using a dose of 10 μg/kg per min and Rhodes et al. using a dose of 5 μg/kg per min reported that patients with an increased oxygen consumption (>15%) in response to dobutamine infusion have a much higher survival rate [30, 31]. This was related to a significant increase in cardiac index and oxygen delivery [30, 31]. More recently, Kumar et al. performed a "dobutamine challenge" at 5, 10, and 15 μg/kg per min in 23 patients with septic shock . They also found that survival was associated with increased cardiac performance and LV contractility indices . In particular, a cutoff value of 8.5 mL/m2 increase in LV stroke index in response to dobutamine correctly categorized the outcome in 21 of 23 patients . Levosimendan, a new calcium sensitizer, also has been proposed to treat septic cardiomyopathy. It may improve not only LV but also RV function in the context of sepsis [33, 34]. Barraud et al. in an endotoxin model in rabbits reported that LV systolic elastance was restored during levosimendan infusion .
Finally, a few words should be mentioned about norepinephrine administration. As explained above and shown in Figure 3, norepinephrine infusion may unmask the impairment of LV contractility. However, some authors recently have suggested that administration of norepinephrine for restoring mean arterial pressure in the early phase of septic shock also increased cardiac output through an increase in both cardiac preload and cardiac contractility . Such findings remain to be confirmed.
Depression of LV intrinsic contractility is constant in patients with septic shock. Because most parameters of cardiac function are strongly dependent on afterload, especially in this context, cardiac performance evaluated at the bedside reflects intrinsic contractility but also the degree of vasoplegia. Recent advances in echocardiography have allowed better characterization of septic cardiomyopathy. Unlike classic cardiomyopathy, it is not associated with high filling pressures for two reasons: increased LV compliance and frequently associated RV dysfunction. It is always reversible. Although it is unclear how septic cardiomyopathy affects outcome, a hyperkinetic state is indicative of profound and persistent vasoplegia associated with a high mortality rate. Preliminary data suggest that the hemodynamic response to dobutamine challenge has a prognostic value, but large studies are required to establish whether inotropic drugs should be used to treat this septic cardiac dysfunction.
Parker M, Shelhamer J, Bacharach S, Green M, Natanson C, Frederick T, Damske B, Parrillo J: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984, 100: 483–490.
Jardin F, Brun-Ney D, Auvert B, Beauchet A, Bourdarias JP: Sepsis-related cardiogenic shock. Crit Care Med 1990, 18: 1055–1060. 10.1097/00003246-199010000-00001
Natanson C, Danner RL, Elin RJ, Hosseini JM, Peart KW, Banks SM, MacVittie TJ, Walker RI, Parrillo JE: Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest 1989, 83: 243–251. 10.1172/JCI113866
Barraud D, Faivre V, Damy T, Welschbillig S, Gayat E, Heymes C, Payen D, Shah A, Mebazaa A: Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med 2007, 35: 1376–1382. 10.1097/01.CCM.0000261889.18102.84
Vieillard-Baron A, Prin S, Chergui K, Dubourg O, Jardin F: Hemodynamic instability in sepsis. Bedside assessment by Doppler echocardiography. Am J Respir Crit Care Med 2003, 168: 1270–1276. 10.1164/rccm.200306-816CC
Cunnion RE, Schaer GK, Parker MM, Natanson C, Parrillo JE: The coronary circulation in human septic shock. Circulation 1986, 73: 637–644.
Dhainaut JF, Huyghebaert MF, Monsallier JF, Lefevre G, Dall'Avasantucci J, Brunet F, Villemant D, Carli A, Raichvarg D: Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987, 75: 533–541.
Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W: A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985, 76: 1539–1553. 10.1172/JCI112135
Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE: Endotoxin and tumor necrosis factor challenges in dogs stimulate the cardiovascular profile of human septic shock. J Exp Med 1989, 169: 823–832. 10.1084/jem.169.3.823
Hollenberg SM, Cunnion RE, Lawrence M: Tumor necrosis factor depress myocardial cell function: results using an in vitro assay of myocyte performance. Clin Res 1989, 37: 528–534.
Kumar A, Thota V, Dee L, Olson J, Parrillo JE: Tumor necrosis factor-alpha and interleukin-1 beta are responsible for depression of in-vitro myocardial cell contractility induced by serum from human septic shock. J Exp Med 1996, 183: 949–958. 10.1084/jem.183.3.949
Kumar A, Brar R, Wang P, Dee L, Skorupa G, Khadour F, Schulz R, Parrillo JE: Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol 1999, 276: R265-R276.
Levy RJ, Piel DA, Acton PD: Evidence of myocardial hibernation in the septic heart. Crit Care Med 2005, 33: 2752–2756. 10.1097/01.CCM.0000189943.60945.77
Tavernier B, Li JM, El-Omar MM, Lanone S, Yang ZK, Trayer IP, Mebazaa A, Shah AM: Cardiac contractility impairment associated with increased phosphorylation of troponin I in endotoxemic rats. Faseb J 2001, 15: 294–296.
Jardin F, Fourme T, Page B, Loubières Y, Vieillard-Baron A, Beauchet A, Bourdarias JP: Persistent preload defect in severe sepsis despite fluid loading: a longitudinal echocardiographic study in patients with septic shock. Chest 1999, 116: 1354–1359. 10.1378/chest.116.5.1354
Bouhemad B, Nicolas-Robin A, Arbelot C, Arthaud M, Féger F, Rouby JJ: Acute left ventricular dilatation and shock-induced myocardial dysfunction. Crit Care Med 2009, 37: 441–447. 10.1097/CCM.0b013e318194ac44
Vincent JL, Reuse C, Frank N, Contempré B, Kahn RJ: Right ventricular dysfunction in septic shock: assessment by measurements of right ventricular ejection fraction using thermodilution technique. Acta Anaesthesiol Scand 1989, 33: 34–38. 10.1111/j.1399-6576.1989.tb02856.x
Kimchi A, Ellrodt AG, Berman DS, Riedinger MS, Swan HJC, Murata GH: Right ventricular performance in septic shock: A combined radionuclide and hemodynamic study. J Am Coll Cardiol 1984, 4: 945–951. 10.1016/S0735-1097(84)80055-8
Parker MM, McCarthy KE, Ognibene FP, Parrillo JE: Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 1990, 97: 126–131. 10.1378/chest.97.1.126
Vieillard-Baron A, Schmitt JM, Beauchet A, Augarde R, Prin S, Page B, Jardin F: Early preload adaptation in septic shock? A transesophageal echocardiographic study. Anesthesiology 2001, 94: 400–406. 10.1097/00000542-200103000-00007
Schneider AJ, Teule GJ, Groeneveld AB, Nauta J, Heidendal GA, Thijs LG: Biventricular performance during volume loading in patients with early septic shock, with emphasis on the right ventricle: a combined hemodynamic and radionuclide study. Am Heart J 1988, 116: 103–112. 10.1016/0002-8703(88)90256-6
Etchecopar-Chevreuil C, François B, Clavel M, Pichon N, Gastinne H, Vignon P: Cardiac morphological and functional changes during early septic shock: a transesophageal echocardiographic study. Intensive Care Med 2008, 34: 250–256. 10.1007/s00134-007-0929-z
Suffredini A, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989, 321: 280–287. 10.1056/NEJM198908033210503
Robotham JL, Takata M, Berman M, Harasawa Y: Ejection fraction revisited. Anesthesiology 1991, 74: 172–183. 10.1097/00000542-199101000-00026
Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F: Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 2008, 36: 1701–1706. 10.1097/CCM.0b013e318174db05
Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D: Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34: 344–353. 10.1097/01.CCM.0000194725.48928.3A
Boyd JH, Forbes J, Nakada TA, Walley K, Russel JA: Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011, 39: 259–265. 10.1097/CCM.0b013e3181feeb15
Ognibene F, Parker M, Natanson C, Shelhamer J, Parrillo J: Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. Chest 1988, 93: 903–910. 10.1378/chest.93.5.903
Vincent JL, Roman A, Kahn RJ: Dobutamine administration in septic shock: addition to a standard protocol. Crit Care Med 1990, 18: 689–693. 10.1097/00003246-199007000-00001
Vallet B, Chopin C, Curtis SE, Dupuis BA, Fourrier F, Mehdaoui H, Leroy B, Rime A, Santre C, Herbecq : Prognostic value of the dobutamine test in patients with sepsis syndrome and normal lactate values: a prospective, multicenter study. Crit Care Med 1993, 21: 1868–1875. 10.1097/00003246-199312000-00014
Rhodes A, Lamb FJ, Malagon I, Newman PJ, Grounds RM, Bennett ED: A prospective study of the use of a dobutamine stress test to identify outcome in patients with sepsis, severe sepsis, or septic shock. Crit Care Med 1999, 27: 2361–2366. 10.1097/00003246-199911000-00007
Kumar A, Schupp E, Bunnell E, Ali A, Milcarek B, Parrillo J: Cardiovascular response to dobutamine stress predicts outcome in severe sepsis and septic shock. Crit Care 2008, 12: R35. 10.1186/cc6814
Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, De Luca L, Di Angelantonio E, Orecchioni A, Pandian N, Pietropaoli P: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005, 31: 638–644. 10.1007/s00134-005-2619-z
Morelli A, Teboul JL, Maggiore SM, Vieillard-Baron A, Rocco M, Conti G, De Gaetano A, Picchini U, Orecchioni A, Carbone I, Tritapepe L, Pietropaoli P, Westpheal M: Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006, 34: 2287–2293. 10.1097/01.CCM.0000230244.17174.4F
Hamzaoui O, Georger JF, Monnet X, Ksouri H, Maizel J, Richard C, Teboul JL: Early administration of norepinephrine increases cardiac preload and cardiac output in septic patients with life-threatening hypotension. Crit Care 2010, 14: R142. 10.1186/cc9207
The author declares that they have no competing interests.
About this article
Cite this article
Vieillard-Baron, A. Septic cardiomyopathy. Ann. Intensive Care 1, 6 (2011). https://doi.org/10.1186/2110-5820-1-6